Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 15Head & Neck 7Gastrointestinal 5Tumor-Agnostic 4Genitourinary 3Endocrine 3Breast 3Plasma cell 1Other solid neoplasm 1Gynecologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 315Bortezomib 166Lenalidomide 132pomalidomide 113daratumumab 96carfilzomib 69Cyclophosphamide 44Calcium Dobesilate 41belantamab mafodotin 32elotuzumab 31fludarabine 27ixazomib 24isatuximab 21Melphalan 21venetoclax 18selinexor 17talquetamab 15Prednisone 15plerixafor 14Panobinostat 14Granulocyte Colony-Stimulating Factor 14Injections 12idecabtagene vicleucel 11Zoledronic Acid 11Thalidomide 11Azacitidine 11pembrolizumab 10tocilizumab 9nirogacestat 9liposomal doxorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × vandetanib × Plasma cell × Clear all
NCT00047788 2016-08-24

Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer

Sanofi

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡